Effect of R-(+)-alpha-lipoic acid on experimental diabetic retinopathy

Area of Science:

• Biochemistry
• Diabetology
• Ophthalmology

Background:

• Diabetes mellitus is characterized by hyperglycemia, leading to mitochondrial overproduction of reactive oxygen species (ROS), a key factor in endothelial damage.
• R-(+)-alpha-lipoic acid, an antioxidant, demonstrates unique properties including mitochondrial distribution, regeneration via glycolytic flux, and a low redox potential, suggesting therapeutic potential.

Purpose of the Study:

• To investigate the efficacy of R-(+)-alpha-lipoic acid in preventing microvascular damage in experimental diabetic retinopathy.
• To assess the impact of R-(+)-alpha-lipoic acid on oxidative stress markers, cellular damage, and key signaling pathways involved in diabetic retinopathy.

Main Methods:

• A study involving three groups of Wistar rats: non-diabetic controls, untreated diabetic controls, and diabetic rats treated with R-(+)-alpha-lipoic acid (60 mg/kg bodyweight i.p. for 30 weeks).
• Quantitative retinal morphometry was performed to count acellular occluded capillaries and pericytes.
• Immunoblotting and electrophoretic mobility shift assays were used to evaluate oxidative stress, advanced glycation end products (AGEs), nuclear factor kappa B (NFkappaB) activation, angiopoietin-2, and vascular endothelial growth factors.

Main Results:

• Diabetic rats exhibited a significant increase in acellular capillaries (57.1/mm(2)) compared to non-diabetic controls (19.8/mm(2)), which was reduced by 88% with R-(+)-alpha-lipoic acid treatment (p<0.001).
• Pericyte loss was significantly inhibited in treated diabetic rats (1,656/mm(2)) compared to untreated diabetic rats (1,294/mm(2)) (p<0.01).
• R-(+)-alpha-lipoic acid treatment significantly reduced oxidative stress, normalized NFkappaB activation and angiopoietin-2 expression, and decreased vascular endothelial growth factor by 43% (p<0.0001).

Conclusions:

• R-(+)-alpha-lipoic acid effectively prevents microvascular damage in experimental diabetic retinopathy.
• The compound normalizes pathways downstream of mitochondrial ROS overproduction and preserves pericyte coverage, offering endothelial protection.
• These findings highlight R-(+)-alpha-lipoic acid as a potential therapeutic agent for diabetic retinopathy by mitigating oxidative stress and preserving retinal vasculature.